Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
DXD0YP
|
||||
Drug Name |
N-(3-(4-benzamido-1H-pyrrolo[3,2-c]pyridin-1-yl)phenyl)-4-morpholino-3-(trifluoromethyl)benzamide
|
||||
Synonyms |
CHEMBL1084450
|
||||
Indication | Discovery agent | Investigative | [1587926] | ||
Formula |
C32H26F3N5O3
|
||||
Canonical SMILES |
FC(F)(F)c1cc(ccc1N2CCOCC2)C(=O)Nc3cccc(c3)n4ccc5c(NC(=O)c6ccccc6)nccc45
|
||||
InChI |
InChI=1S/C32H26F3N5O3/c33-32(34,35)26-19-22(9-10-28(26)39-15-17-43-18-16-39)31(42)37-23-7-4-8-24(20-23)40-14-12-25-27(40)11-13-36-29(25)38-30(41)21-5-2-1-3-6-21/h1-14,19-20H,15-18H2,(H,37,42)(H,36,38,41)
|
||||
InChIKey |
FDCXXPBBHPICRU-UHFFFAOYSA-N
|
||||
Target and Pathway | |||||
Target(s) | Vascular endothelial growth factor receptor 2 | Target Info | [1587926] | ||
FL cytokine receptor | Target Info | [1587926] | |||
KEGG Pathway | Ras signaling pathway | ||||
Rap1 signaling pathway | |||||
Cytokine-cytokine receptor interaction | |||||
Endocytosis | |||||
PI3K-Akt signaling pathway | |||||
VEGF signaling pathway | |||||
Focal adhesion | |||||
Proteoglycans in cancerhsa04060:Cytokine-cytokine receptor interaction | |||||
Hematopoietic cell lineage | |||||
Pathways in cancer | |||||
Transcriptional misregulation in cancer | |||||
Acute myeloid leukemia | |||||
Central carbon metabolism in cancer | |||||
NetPath Pathway | IL2 Signaling Pathway | ||||
PANTHER Pathway | Angiogenesis | ||||
VEGF signaling pathway | |||||
Pathway Interaction Database | HIF-2-alpha transcription factor network | ||||
Beta3 integrin cell surface interactions | |||||
Signaling events mediated by TCPTP | |||||
SHP2 signaling | |||||
S1P1 pathway | |||||
VEGF and VEGFR signaling network | |||||
Integrins in angiogenesis | |||||
Signaling events mediated by VEGFR1 and VEGFR2 | |||||
Notch-mediated HES/HEY network | |||||
References |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.